National and international developments in cancer, health and policy. Produced in collaboration with the Press Association unless otherwise stated.
The National Institute for Health and Care Excellence has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma.
One in three cancer patients said their treatment was impacted by the effects of COVID-19 on the health system, according to survey results.
The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.
The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England.
Around a quarter of GPs have said that urgent referrals for suspected cancer had been turned down by hospitals more often than before the pandemic.